Indications & formulation #
Maintenance of alcohol abstinence after withdrawal. This reference covers the selected formulation; other indications and products need their own evidence.
Dose reference #
Adult educational reference · Oral delayed-release 333 mg tablet · United States. The clinician selects treatment after assessment; this page does not calculate or change a prescription.
Usual reference: 666 mg three times daily, alongside psychosocial treatment. It does not treat acute alcohol withdrawal.
Contraindications & important cautions #
Contraindicated at CrCl 30 mL/min or below. Assess mood/suicidality and diarrhea.
Selected important cautions; consult the full product information for all contraindications and warnings.
Adverse effects #
Diarrhea and mood-related concerns.
Interactions #
Few metabolic interactions; renal clearance governs suitability.
Monitoring #
Review renal function, abstinence goals, adherence and mood.
Special populations #
CrCl above 30 through 50: 333 mg three times daily. Renal assessment is essential, particularly in older adults.
Adult scope. Pregnancy, breastfeeding and pediatric use require the exact product’s population-specific guidance and individual assessment.
Discontinuation, restarting & counseling #
A lapse does not automatically require stopping; review drinking, adherence and the continuing recovery plan.
Condition-specific prescribing #
Additional indication-specific records retain their own formulation and source context.
Acamprosate
Maintenance of alcohol abstinence after withdrawal
Adults · 333 mg delayed-release tablets · Oral · US label regimen; duration from UK NICE. Indian authorization not established here.
- Starting dose
- 666 mg three times daily after abstinence is achieved.
- Titration
- No routine upward titration in this label.
- Treatment range / target
- 666 mg three times daily (1,998 mg/day).
- Maximum / limits
- 1,998 mg/day is the recommended regimen; higher dosing is not supplied here.
- Trial & duration
- Reassess ongoing benefit; NICE generally uses 6 months, longer if beneficial.
- Monitoring
- Renal function, adherence, diarrhoea and emerging depression or suicidality.
- Population & organ-function adjustments
- US label: creatinine clearance 30–50 mL/min: 333 mg three times daily; contraindicated at ≤30 mL/min.
- Important cautions
- Does not treat acute withdrawal. Use with psychosocial care. UK weight-based and renal rules differ.
Brands & products #
Historical catalogue observations. Prices and catalogue presence do not establish current availability or Indian approval.
Reference coverage #
Structured summary of selected adult uses, not an exhaustive monograph. Indian product authorization and local prescribing requirements have not been reconciled.
References · 3
- Acamprosate — Oral delayed-release 333 mg tablet — selected prescribing information · United States · Checked 2026-10-27 · Selected formulation: Oral delayed-release 333 mg tablet · Supports indications, dose, cautions, adverse effects, interactions, monitoring, special populations and stopping. Source sections: Indications and usage; Dosage and administration; Contraindications; warnings and precautions; Use in specific populations; patient counseling
- Acamprosate delayed-release tablets: US label · United States; DailyMed submitted label · Checked 2026-10-26 · Supports: Acamprosate — Maintenance of alcohol abstinence after withdrawal (333 mg delayed-release tablets)
- NICE CG115: alcohol dependence · United Kingdom · Checked 2026-10-26 · Supports: Acamprosate — Maintenance of alcohol abstinence after withdrawal (333 mg delayed-release tablets)